What patient specific factors outside of health insurance coverage do you use to decide which GLP1 R agonist or dual agonist therapy to start in patients with diabetes?

The class of drugs called GLP 1 RA continues to grow. Single agonist drugs include dulaglutide and semaglutide. There is now a “dual agonist” available for use, tirzepatide, which really is a GLP 1 RA and GIP RA. There are “triple agonists” which also bind the glucagon receptor that are close to FDA...

Usually it has to do with the following factors

1. Difficulty manipulating objects/eyesight issues. The Trulicity pen tends to be easier to function, as it doesn't need to have needles installed, and the ample base makes it easier for patients that may have hand/eye coordination issues.
2. Need to titrat...

I generally favor semaglutide or tirzepatide when coverage is not an issue, particularly when greater weight loss and glycemic efficacy are priorities. However, I individualize therapy based on GI tolerance, comorbidities, cardiovascular risk, and prior experience with the class, if any. Some patien...